Ninlaro (ixazomib) / Takeda  >>  Phase 2
Welcome,         Profile    Billing    Logout  

110 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ninlaro (ixazomib) / Takeda
PrE0404, NCT03323151: A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

Completed
1/2
43
US
Ixazomib, Ninlaro, Ibrutinib, Imbruvica
PrECOG, LLC., Takeda
Mantle-Cell Lymphoma
09/22
09/23
NCT03225417 / 2016-002503-26: Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.

Active, not recruiting
1/2
142
Europe
Ixazomib, X16082, Tacrolimus, Prograf, Sirolimus, Rapamune, Any prophylaxis for GVHD, Any prophylaxis for GVHD, except antithymocyte globulin, cyclophosphamide or any in vitro or in vivo.
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Hematopoietic Stem Cell Transplantation, Multiple Myeloma
01/24
12/24
NCT02632396: Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission

Active, not recruiting
1/2
12
US
Ixazomib, Ninlaro, MLN9708, Ixazomib Citrate, Rituximab, Rituxan, MabThera, Chimeric Anti-CD20 Antibody
Emory University, Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)
Mantle Cell Lymphoma
08/23
08/24
T2017-002, NCT03817320 / 2019-001947-28: PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Active, not recruiting
1/2
31
US, RoW
Ixazomib, Vincristine, Dexamethasone, Asparaginase, Doxorubicin, Methotrexate (IT), Triple IT (Methotrexate, Hydrocortisone, Cytarabine), Leucovorin
Therapeutic Advances in Childhood Leukemia Consortium, Takeda, Children's Hospital Los Angeles
ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood
12/24
06/25
NCT04094961: Ixazomib + Pomalidomide + Dexamethasone In MM

Recruiting
1/2
61
US
Ixazomib, Ninlaro®, Pomalidomide, Pomalyst®, Dexamethasone, Baycadron, Decadron, Dexamethasone Intensol, DexPak, TaperDex, Zema-Pak, ZoDex, Zonacort
Omar Nadeem, MD, Takeda
Multiple Myeloma, Multiple Myeloma in Relapse
12/24
12/24
NCT02542657: Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma

Active, not recruiting
1/2
30
US
Clarithromycin, Biaxin, Dexamethasone, Decadron, Ixazomib Citrate, MLN9708, Pomalidomide, Pomalyst
Joseph Tuscano, Takeda, Celgene
Myeloma
08/24
12/24
NCT02420847: Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

Active, not recruiting
1/2
57
US
Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Urothelial Carcinoma, Transitional Cell Carcinoma, Unresectable Transitional Cell Carcinoma
12/25
12/25
STOMP, NCT02343042: Selinexor and Backbone Treatments of Multiple Myeloma Patients

Checkmark From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Jun 2021 - Jun 2021: From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Checkmark Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
Dec 2020 - Dec 2020: Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
Checkmark Data from STOMP trial in combination with carfilzomib and dexamethasone for multiple myeloma at ASH 2020
More
Active, not recruiting
1/2
300
Canada, US
Selinexor, KPT-330, XPOVIO®, Dexamethasone, Decadron®, Lenalidomide, Revlimid®, Pomalidomide, Pomalyst®, Bortezomib, Velcade®, Daratumumab, Darzalex®, Carfilzomib, Kyprolis®, Ixazomib, Ninlaro®, Elotuzumab, Empliciti®, Clarithromycin, Biaxin, Belantamab Mafodotin, BLENREP, Mezigdomide, BMS-986348, CC-92480
Karyopharm Therapeutics Inc, Bristol-Myers Squibb
Multiple Myeloma
04/27
04/27
NCT05451771: Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Recruiting
1/2
53
US
Venetoclax Oral Tablet, 200 mg, Venclexta, FISH assay, t(11;14) FISH assay, Venetoclax Oral Tablet, 400 mg, Dexamethasone Oral, 10 mg, Decadron, Hemady, Dexamethasone Oral, 20 mg, Daratumumab Injection, Darzalex, Bendamustine, Treanda, Pomalidomide, Pomalyst, Ixazomib, Ninlaro, Venetoclax MTD with Dexamethasone
Rajshekhar Chakraborty, MD, Genentech, Inc.
AL Amyloidosis
09/26
09/26
NCT06050512: Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Recruiting
1/2
34
US
Mezigdomide, CC-92480, MEZI, Ixazomib, NINLARO®, Dexamethasone, Dex
Kathleen Dorritie, Bristol-Myers Squibb
Relapsed and Refractory Multiple Myeloma
10/26
10/26
 

Download Options